Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
BB Biotech AG (BBZA) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of BB Biotech AG €190, price €53.90, upside +252.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
BB
Thin data
Sep 24, 2026
BB Biotech AG
BBZA · XETRAClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value €189.72 · Strongly undervalued (+252.0%)
✓Quality 70/100
!Weak Growth (revenue 5y −3.4 %/yr)
✓Highly profitable · 127.3% net margin (TTM)
✓generates free cash flow
✓4.2% dividend yield · Well covered
!Moderate moat 58/100
!Evidence only low, so the estimate is less certain
!The models disagree: range €102.02 to €373.40
Watch BB Biotech AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €25.82 – €66.33 · fair‑value band €102.02 – €373.40 · the €53.90 price screens below the €189.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio.
Show more
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Stock analysis
BB Biotech AG (BBZA) currently trades at €53.90, while our model-based Fair Value estimate is €189.72, implying the stock looks roughly 71.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €522.01 per share, and 17 of the 22 models we run sit above the €53.90 price.
Bear case: the Dividend Discount group reads lowest at €28.95, and 5 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: €102.02 (bear) to €373.40 (bull), the price of €53.90 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
BB Biotech AG reported revenue of CHF 587M in FY2025 versus −CHF 396M in FY2021. Reported net income was CHF 578M in FY2025.
Key figures
Market cap €3.2B · P/S ratio 3.13 · EPS (TTM) €−8.60 · Dividend yield 4.2% · Net margin 98.5% · Return on equity 54.8% · Return on assets (EBIT) −1.2% · Operating margin 97.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 252%, BBZA screens cheaper than that median.
Fair Value models
Bear €102.02
Fair Value €189.72
Bull €373.40
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
€95.23
€109.96
€122.67
70
FCF DCF
€97.48
€149.06
€309.87
69
Growth DCF
€91.66
€172.75
€303.39
68
All 22 models by family
DCF Models
FCF DCF
€97.48
€149.06
€309.87
69
5Y Revenue Exit
€48.18
€72.39
€122.26
64
5Y P/E Exit
€166.12
€390.89
€700.96
60
10Y Revenue Exit
€62.71
€113.01
€138.09
61
10Y P/E Exit
€147.88
€361.15
€720.13
53
Earnings-Based
Graham-Dodd
€76.40
€532.82
€747.74
59
Lynch FV
€275.28
€393.25
€511.23
57
PEG = 1.0
€275.28
€393.25
€511.23
54
EPV
€95.23
€109.96
€122.67
70
Dividend Discount
Gordon GGM
€16.81
€33.50
€50.72
63
DDM Multi-Stage
€16.81
€28.95
€35.36
63
Multiples
P/E Multiple
€185.39
€247.19
€308.98
63
P/S Multiple
€29.95
€39.93
€49.91
58
P/B Multiple
€143.26
€191.01
€238.76
55
EV/EBIT
€147.33
€195.80
€244.28
63
EV/Revenue
€25.87
€36.13
€46.40
51
Asset-Based
NCAV (Graham)
€27.00
€36.18
€54.00
51
Growth DCF
Growth DCF
€91.66
€172.75
€303.39
68
Rev-Margin DCF
€52.41
€82.69
€143.35
64
Economic Profit
Residual Income
€71.55
€101.31
€199.45
67
ROIC Compounder
€128.10
€196.95
€239.41
66
Growth Earnings
Growth-Adj P/E
€365.41
€522.01
€678.62
64
Notify me when BBZA reaches fair value
Put BBZA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
70/100
Of which business quality 70 · Market factors (momentum, volatility) 72
Profitability
57
Margins and returns on capital today
Quality Growth
80
Are margins and returns improving?
Cashflow
76
Earnings quality: real cash, not paper profit
Fin. Strength
82
Balance sheet, leverage, solvency risk
Investment
98
Disciplined investing over empire-building
Low Volatility
84
Calm price path (market factor)
Momentum
62
Price trend over the last 3–12 months (market factor)
52W Momentum
75
Distance to the 52-week high (market factor)
Net Issuance
27
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+425.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.4%
Start year 2020 (pandemic). Over 10 years: −1.2% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’08
’09
’10
’12
’13
’14
’15
’17
’19
’20
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.2%
Dividend (yield on the price)4.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.2% vs −5.7%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.99% → 100%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 18.9%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −7.3% a year for the price.
Watch BBZA, get fair value alerts →
Compare BB Biotech AG with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 624 stocks
Beats the industry median on 11/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: German Stocks
- Valuation of the Germany market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is BB Biotech AG (BBZA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €189.72 versus a price of €53.90, about +252% upside (undervalued).
What is the fair value of BBZA?
Our model-based fair value for BB Biotech AG is €189.72 (as of Sep 24, 2026), built from audited fundamentals. The current price: €53.90.
What is the quality score of BBZA?
BB Biotech AG has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BB Biotech AG (BBZA)?
Our model-based price target is the fair value of €189.72 (as of Sep 24, 2026) from 22 valuation models. Cautious scenario €102.02, optimistic scenario €373.40. It is a calculation from audited fundamentals, not an analyst target.
What is the BB Biotech AG stock forecast for 2026?
Our models put fair value at €189.72, about +252% upside versus a price of €53.90 (undervalued). Cautious scenario €102.02, optimistic scenario €373.40. The calculation is refreshed regularly with new filings.
What is the revenue of BB Biotech AG (BBZA)?
BB Biotech AG reported trailing-twelve-month revenue of about €1.1B (latest available figure, as of Sep 24, 2026).
Does BB Biotech AG pay a dividend?
BB Biotech AG currently shows a dividend yield of about 4.17% relative to its recent price (as of Sep 24, 2026).
What growth is priced into BB Biotech AG (BBZA)?
For today's price to be fair in a discounted-cash-flow model, BB Biotech AG would have to grow free cash flow by -5.2 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -3.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BBZA use?
Our models discount BB Biotech AG at 8.7 %: a base by market capitalisation (mid), damped by beta 0.66, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BB Biotech AG that is -5.2 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has BB Biotech AG (BBZA) delivered so far?
Over the past 5 years revenue at BB Biotech AG grew -3.4 % a year. The price currently implies -5.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BB Biotech AG (BBZA) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into BB Biotech AG (-5.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BB Biotech AG (BBZA)?
The free-cash-flow yield on the price is 9.60 %: that much free cash flow BB Biotech AG produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BB Biotech AG (BBZA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BB Biotech AG it is €189.72 per share (as of Sep 24, 2026), against a price of €53.90. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is BB Biotech AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BBZA trades below its calculated fair value: price €53.90, fair value €189.72, a gap of about +252% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BBZA?
No. The price is what the market pays today (€53.90); the fair value is what the company's own numbers justify (€189.72). For BB Biotech AG the two are €135.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is BB Biotech AG worth?
The market values BB Biotech AG at about €3.2B (market capitalisation, as of Sep 24, 2026). Per share that is €53.90; our models calculate a fair value of €189.72 per share.
What do the bullish and bearish scenarios say about BBZA?
Our models span a range for BB Biotech AG: cautious scenario €102.02, base €189.72, optimistic €373.40 per share (as of Sep 24, 2026, price €53.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BB Biotech AG (BBZA)?
Balance-sheet figures for BB Biotech AG (as of Sep 24, 2026): return on equity 54.8%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is BBZA from its 52-week high?
BB Biotech AG trades at €53.90, about 11% below its 52-week high of €60.50 and 45% above the low of €37.18 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €189.72 is for.
Which stocks are comparable to BB Biotech AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BB Biotech AG stock attractive at the current price?
The data as of Sep 24, 2026: price €53.90, calculated fair value €189.72 (+252%), Quality Score 70/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BBZA calculated?
We run BB Biotech AG through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €189.72, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BB Biotech AG currently trades 72 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BB Biotech AG (BBZA)?
The closing price on Oct 2, 2026 was €53.90. Our model-based fair value is €189.72, about +252% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BB Biotech AG right now?
The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€102.02). The market is more pessimistic than our downside scenario. The model range is unusually wide (€102.02 to €373.40). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of BB Biotech AG (BBZA) come from?
Earnings per share at BB Biotech AG grew −10.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share −10.4 %, EBIT margin −0.3 %, tax rate +0.0 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of BB Biotech AG
How large is the market capitalisation of BB Biotech AG (BBZA)?
The market capitalisation of BB Biotech AG is €3.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BB Biotech AG (BBZA)?
The price-to-sales ratio of BB Biotech AG is 3.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BB Biotech AG (BBZA)?
Earnings per share at BB Biotech AG are €−8.60. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BB Biotech AG (BBZA)?
The dividend yield of BB Biotech AG is 4.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BB Biotech AG (BBZA)?
The net margin of BB Biotech AG is 98.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BB Biotech AG (BBZA)?
The return on equity (ROE) of BB Biotech AG is 54.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BB Biotech AG (BBZA)?
On an EBIT basis the return on assets of BB Biotech AG is −1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BB Biotech AG (BBZA)?
The operating margin of BB Biotech AG is 97.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at BB Biotech AG (BBZA)?
Earnings per share at BB Biotech AG are growing +692% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BB Biotech AG (BBZA) hold?
BB Biotech AG holds more cash than debt, €98.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BB Biotech AG in the live analysis
One click puts BB Biotech AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.